D amour J, Magagna Poveda A, Moretto J, Friedman D, Lafrancois J, Pearce P, et al. Interictal spike frequency varies with ovarian cycle stage in a rat model of epilepsy. Exp Neurol. 2015;269:102-19 pubmed publisher

Bartonkova I, Novotna A, Dvorak Z. Novel stably transfected human reporter cell line AIZ-AR as a tool for an assessment of human androgen receptor transcriptional activity. PLoS ONE. 2015;10:e0121316 pubmed publisher

Vidugiriene J, Leippe D, Sobol M, Vidugiris G, Zhou W, Meisenheimer P, et al. Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening. Assay Drug Dev Technol. 2014;12:514-26 pubmed publisher

Nichols H, DeRoo L, Scharf D, Sandler D. Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst. 2015;107:354 pubmed publisher

Ishihara Y, Itoh K, Ishida A, Yamazaki T. Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway. J Steroid Biochem Mol Biol. 2015;145:85-93 pubmed publisher

Hermansen L, Sørensen M, Barckman J, Bechtold J, Søballe K, Baas J. Incorporation of raloxifene-impregnated allograft around orthopedic titanium implants impairs early fixation but improves new bone formation. Acta Orthop. 2015;86:127-33 pubmed publisher

Abdelazim I, Abdelrazak K, Al Kadi M, Yehia A, Nusair B, Faza M. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis. Arch Osteoporos. 2014;9:189 pubmed publisher

Inoue K, Mizuo H, Kawaguchi S, Fukuda K, Kusano K, Yoshimura T. Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase. Drug Metab Dispos. 2014;42:1326-33 pubmed publisher

Tran T, Ramasamy T, Cho H, Kim Y, Poudel B, Choi H, et al. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. J Nanosci Nanotechnol. 2014;14:4820-31 pubmed

Fontana R, Della Torre S, Meda C, Longo A, Eva C, Maggi A. Estrogen replacement therapy regulation of energy metabolism in female mouse hypothalamus. Endocrinology. 2014;155:2213-21 pubmed publisher

. Experts add second drug to breast cancer prevention regimen. Harv Womens Health Watch. 2013;21:8 pubmed

. Summaries for patients. Using medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159:I-28 pubmed

Pinkerton J, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142-54 pubmed publisher

Moyer V. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:698-708 pubmed publisher

Wise J. NICE recommends preventive drugs for breast cancer. BMJ. 2013;346:f4116 pubmed publisher

Grove E, Abrahamsen B, Vestergaard P. Heart failure in patients treated with bisphosphonates. J Intern Med. 2013;274:342-50 pubmed publisher

Unkila M, Kari S, Yatkin E, Lammintausta R. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol. 2013;138:107-15 pubmed publisher

Kumar P, Song Z. Identification of raloxifene as a novel CB2 inverse agonist. Biochem Biophys Res Commun. 2013;435:76-81 pubmed publisher

McCarthy M. Breast cancer drugs should be offered to healthy but high risk women, US panel concludes. BMJ. 2013;346:f2499 pubmed publisher

Nelson H, Smith M, Griffin J, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:604-14 pubmed publisher

Mendoza Edroso C, Sánchez Garrido Lestache N, López Picado A. [Postmenopausal osteoporosis: Primary prevention or excessive use of medications]. Semergen. 2013;39:123-9 pubmed publisher

Foster S, Shi N, Curkendall S, Stock J, Chu B, Burge R, et al. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013;13:15 pubmed publisher

Daniels L, Grady D, Mosca L, Collins P, Mitlak B, Amewou Atisso M, et al. Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial. Circ Cardiovasc Qual Outcomes. 2013;6:164-70 pubmed publisher

Budoff M. Diabetes mellitus in women can be RUTHless: lessons from the Raloxifene Use for The Heart (RUTH) Trial. Circ Cardiovasc Qual Outcomes. 2013;6:137-8 pubmed publisher

Liu S, Han S, Smith C. Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes. Mol Pharmacol. 2013;83:1066-77 pubmed publisher

Kavas A, Cagatay S, Banerjee S, Keskin D, Tezcaner A. Potential of Raloxifene in reversing osteoarthritis-like alterations in rat chondrocytes: an in vitro model study. J Biosci. 2013;38:135-47 pubmed

Briongos L, Sañudo S, Garcia Alonso M, Ruiz Mambrilla M, Duenas Laita A, Perez Castrillon J. Treatment of osteoporosis and hip fractures in a Spanish health area. Eur Rev Med Pharmacol Sci. 2013;17:266-8 pubmed

Cook I, Wang T, Almo S, Kim J, Falany C, Leyh T. Testing the sulfotransferase molecular pore hypothesis. J Biol Chem. 2013;288:8619-26 pubmed publisher

Schaid D, Jenkins G, Ingle J, Weinshilboum R. Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies. Genet Epidemiol. 2013;37:229-38 pubmed publisher

Nishi Y, Satoh M, Nagasu H, Kadoya H, Ihoriya C, Kidokoro K, et al. Selective estrogen receptor modulation attenuates proteinuria-induced renal tubular damage by modulating mitochondrial oxidative status. Kidney Int. 2013;83:662-73 pubmed publisher

Tran T, Poudel B, Marasini N, Woo J, Choi H, Yong C, et al. Development of raloxifene-solid dispersion with improved oral bioavailability via spray-drying technique. Arch Pharm Res. 2013;36:86-93 pubmed publisher

Ando H, Otoda T, Ookami H, Nagai Y, Inano A, Takamura T, et al. Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis. Clin Exp Pharmacol Physiol. 2013;40:227-32 pubmed publisher

Tran T, Poudel B, Marasini N, Chi S, Choi H, Yong C, et al. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent. Int J Pharm. 2013;443:50-7 pubmed publisher

. Breast cancer facts. J Okla State Med Assoc. 2012;105:411-2 pubmed

Yadav A, Carey E. Osteoporosis in chronic liver disease. Nutr Clin Pract. 2013;28:52-64 pubmed publisher

Takeda S, Sakai S, Shiraishi A, Koike N, Mihara M, Endo K. Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats. Bone. 2013;53:167-73 pubmed publisher

Westphal C, Schubert C, Prelle K, Penkalla A, Fliegner D, Petrov G, et al. Effects of estrogen, an ER? agonist and raloxifene on pressure overload induced cardiac hypertrophy. PLoS ONE. 2012;7:e50802 pubmed publisher

Ismailoglu O, Oral B, Sutcu R, Kara Y, Tomruk O, Demir N. Neuroprotective effects of raloxifene on experimental spinal cord injury in rats. Am J Med Sci. 2013;345:39-44 pubmed publisher

Martins Maciel E, Campos L, Salgueiro Pagadigorria C, Bracht A, Ishii Iwamoto E. Raloxifene affects fatty acid oxidation in livers from ovariectomized rats by acting as a pro-oxidant agent. Toxicol Lett. 2013;217:82-9 pubmed publisher

Sadhu K, Eierhoff T, Römer W, Winssinger N. Photoreductive uncaging of fluorophore in response to protein oligomers by templated reaction in vitro and in cellulo. J Am Chem Soc. 2012;134:20013-6 pubmed publisher

Vlachopoulos C, Xaplanteris P, Stefanadis C. Raloxifene, arterial function and Ockham's razor. Vascul Pharmacol. 2013;58:1-2 pubmed publisher

Rodrigues Junior D, Lopes Costa P, dos Santos A, da Silva B. Effects of tamoxifen and raloxifene on body and uterine weights of rats in persistent estrus. Clin Exp Obstet Gynecol. 2012;39:362-4 pubmed

Coopey S, Mazzola E, Buckley J, Sharko J, Belli A, Kim E, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136:627-33 pubmed publisher

Khedr N, El Ashmawy N, El Bahrawy H, Haggag A, El Abd E. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate. Fundam Clin Pharmacol. 2013;27:526-34 pubmed publisher

Barreto G, Santos Galindo M, Diz Chaves Y, Pernia O, Carrero P, Azcoitia I, et al. Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones. Endocrinology. 2009;150:5010-5 pubmed publisher

Kobayashi H, Hamaya E. [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy]. Nihon Yakurigaku Zasshi. 2005;125:37-48 pubmed

Itabashi A. [Raloxifene hydrochloride]. Nihon Rinsho. 2004;62 Suppl 2:528-35 pubmed

Saitta A, Morabito N, Frisina N, Cucinotte D, Corrado F, D Anna R, et al. Cardiovascular effects of raloxifene hydrochloride. Cardiovasc Drug Rev. 2001;19:57-74 pubmed

Snyder K, Sparano N, Malinowski J. Raloxifene hydrochloride. Am J Health Syst Pharm. 2000;57:1669-75; quiz 1676-8 pubmed

Fitzpatrick S, Berrodin T, Jenkins S, Sindoni D, Deecher D, Frail D. Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology. 1999;140:3928-37 pubmed

Khovidhunkit W, Shoback D. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130:431-9 pubmed